Cargando…

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial

BACKGROUND: The primary objective was to determine maximum tolerated radiation dose in patients with metastatic renal cell carcinoma on pazopanib treatment. METHODS: Treatment-naïve patients received pazopanib according to standard of care. Stereotactic body radiotherapy (SBRT) was delivered concurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Wolf, Katrien, Rottey, Sylvie, Vermaelen, Karim, Decaestecker, Karel, Sundahl, Nora, De Lobel, Lizzy, Goetghebeur, Els, De Meerleer, Gert, Lumen, Nicolaas, Fonteyne, Valérie, De Maeseneer, Daan, Ost, Piet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610443/ https://www.ncbi.nlm.nih.gov/pubmed/28938918 http://dx.doi.org/10.1186/s13014-017-0893-x

Ejemplares similares

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
por: Sundahl, Nora, et al.
Publicado: (2017)

Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer
por: Fonteyne, Valérie, et al.
Publicado: (2012)

The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study
por: Poelaert, Filip, et al.
Publicado: (2015)

Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome
por: Claeys, Tom, et al.
Publicado: (2015)

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial
por: Verghote, Flor, et al.
Publicado: (2021)

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy
por: De Wolf, Katrien, et al.
Publicado: (2015)

A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer
por: De Bleser, Elise, et al.
Publicado: (2020)

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
por: Decaestecker, Karel, et al.
Publicado: (2014)

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial
por: Fonteyne, Valérie, et al.
Publicado: (2017)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021)

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial
por: Spaas, Mathieu, et al.
Publicado: (2021)

Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial
por: Draulans, Cédric, et al.
Publicado: (2018)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol
por: Rammant, Elke, et al.
Publicado: (2017)

Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis
por: Vermassen, Tijl, et al.
Publicado: (2015)

Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients
por: Huysse, Wouter, et al.
Publicado: (2017)

Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up
por: De Visschere, Pieter, et al.
Publicado: (2016)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
por: Diéras, Véronique, et al.
Publicado: (2016)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
por: Négrier, Sylvie, et al.
Publicado: (2017)

Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?
por: Helsmoortel, Hetty, et al.
Publicado: (2018)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer
por: De Kerf, Geert, et al.
Publicado: (2023)

A phase I study of pazopanib in combination with escalating doses of (131)I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine
por: Chow, Laura Q., et al.
Publicado: (2017)

A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
por: De Wolf, Katrien, et al.
Publicado: (2017)

Effects of radiation on the metastatic process
por: Sundahl, Nora, et al.
Publicado: (2018)

N-Linked Glycosylation and Near-Infrared Spectroscopy in the Diagnosis of Prostate Cancer
por: Vermassen, Tijl, et al.
Publicado: (2019)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients
por: EL-SAGHIRE, HOUSSEIN, et al.
Publicado: (2014)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Perineal Urethrostomy: Surgical and Functional Evaluation of Two Techniques
por: Lumen, Nicolaas, et al.
Publicado: (2015)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures
por: Meireson, Annabel, et al.
Publicado: (2021)

Anastomotic Repair versus Free Graft Urethroplasty for Bulbar Strictures: A Focus on the Impact on Sexual Function
por: Beysens, Matthias, et al.
Publicado: (2015)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
por: Groenland, Stefanie L., et al.
Publicado: (2018)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ns1dse3pgiap5uqnnk28hmqcp9